NASDAQ: PMCBPharmacyte Biotech Inc Stock
$2.20+0.07 (+3.29%)
Updated Apr 24, 2024
PMCB Price
$2.20
Fair Value Price
$3.49
Market Cap
$18.62M
52 Week Low
$1.92
52 Week High
$3.23
P/E
-1.83x
P/B
0.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.72
Operating Cash Flow
-$2M
Beta
0.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PMCB Overview
PharmaCyte Biotech, Inc. is developing cellular therapies for cancer and diabetes in the U.S. Its therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology. Formerly Nuvilex, Inc., PharmaCyte Biotech was incorporated in 1996 and is headquartered in Laguna Hills, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMCB ($2.20) is undervalued by 36.98% relative to our estimate of its Fair Value price of $3.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PMCB ($2.20) is significantly undervalued by 36.98% relative to our estimate of its Fair Value price of $3.49 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PMCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMCB due diligence checks available for Premium users.
Be the first to know about important PMCB news, forecast changes, insider trades & much more!
PMCB News
Valuation
PMCB fair value
Fair Value of PMCB stock based on Discounted Cash Flow (DCF)
Price
$2.20
Fair Value
$3.49
Undervalued by
36.98%
PMCB ($2.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMCB ($2.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PMCB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
15.69x
Market
41.27x
PMCB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
5.86x
PMCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMCB's financial health
Profit margin
Revenue
$0.0
Net Income
-$619.5k
Profit Margin
0%
PMCB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$71.4M
Liabilities
$22.5M
Debt to equity
0.72
PMCB's short-term assets ($61.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMCB's short-term assets ($61.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMCB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PMCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$177.1k
Investing
-$5.0M
Financing
-$7.0M
PMCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMCB vs Biotech Stocks
Pharmacyte Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.